Key Points
- Director Josef Parvizi sold 16,714 shares on Feb. 19 at an average price of $20.27 (proceeds $338,792.78) and has sold roughly 91,714 shares in recent months; after the Feb. sale he still owns 722,652 shares, a 2.26% reduction in his stake.
- CeriBell (NASDAQ:CBLL) trades near $20 with a market cap around $741.6M and a negative P/E, and analysts hold a consensus "Moderate Buy" with an average price target of $24.67 amid mixed individual targets ranging from $17 to $30.
CeriBell, Inc. (NASDAQ:CBLL - Get Free Report) Director Josef Parvizi sold 16,714 shares of the stock in a transaction that occurred on Thursday, February 19th. The shares were sold at an average price of $20.27, for a total transaction of $338,792.78. Following the completion of the sale, the director owned 722,652 shares in the company, valued at $14,648,156.04. This represents a 2.26% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
Josef Parvizi also recently made the following trade(s):
- On Thursday, January 15th, Josef Parvizi sold 25,000 shares of CeriBell stock. The shares were sold at an average price of $22.94, for a total value of $573,500.00.
- On Monday, December 15th, Josef Parvizi sold 25,000 shares of CeriBell stock. The shares were sold at an average price of $21.49, for a total value of $537,250.00.
- On Monday, December 8th, Josef Parvizi sold 25,000 shares of CeriBell stock. The stock was sold at an average price of $20.26, for a total value of $506,500.00.
CeriBell Stock Down 1.1%
Shares of NASDAQ:CBLL opened at $19.99 on Tuesday. The company has a quick ratio of 12.25, a current ratio of 12.65 and a debt-to-equity ratio of 0.12. The company has a market capitalization of $741.55 million, a P/E ratio of -13.24 and a beta of 1.03. CeriBell, Inc. has a 52-week low of $10.01 and a 52-week high of $26.04. The stock's fifty day simple moving average is $21.30 and its 200-day simple moving average is $16.12.
Analysts Set New Price Targets
CBLL has been the subject of a number of analyst reports. JPMorgan Chase & Co. cut their price objective on shares of CeriBell from $21.00 to $17.00 and set an "overweight" rating for the company in a research report on Wednesday, November 5th. Canaccord Genuity Group lifted their target price on shares of CeriBell from $29.00 to $30.00 and gave the stock a "buy" rating in a research note on Wednesday, December 17th. BTIG Research reissued a "buy" rating and set a $30.00 price target on shares of CeriBell in a research note on Wednesday, January 28th. Finally, TD Cowen reaffirmed a "buy" rating on shares of CeriBell in a research report on Tuesday, December 9th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, CeriBell presently has an average rating of "Moderate Buy" and a consensus price target of $24.67.
View Our Latest Stock Report on CeriBell
Hedge Funds Weigh In On CeriBell
Institutional investors and hedge funds have recently bought and sold shares of the stock. Caitong International Asset Management Co. Ltd boosted its holdings in shares of CeriBell by 3,971.0% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,262 shares of the company's stock valued at $28,000 after purchasing an additional 1,231 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in shares of CeriBell in the 3rd quarter worth $33,000. CWM LLC boosted its holdings in CeriBell by 1,178.5% in the fourth quarter. CWM LLC now owns 1,841 shares of the company's stock valued at $40,000 after acquiring an additional 1,697 shares during the last quarter. Tower Research Capital LLC TRC grew its position in CeriBell by 353.8% during the second quarter. Tower Research Capital LLC TRC now owns 2,310 shares of the company's stock valued at $43,000 after acquiring an additional 1,801 shares during the period. Finally, Ameritas Investment Partners Inc. increased its stake in CeriBell by 97.5% during the second quarter. Ameritas Investment Partners Inc. now owns 2,544 shares of the company's stock worth $48,000 after acquiring an additional 1,256 shares during the last quarter.
CeriBell Company Profile
(
Get Free Report)
CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell's solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.
The company's product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
